China’s Public Hospitals To Dance As Private Insurance Gains Traction?
This article was originally published in PharmAsia News
Executive Summary
China’s health insurance sector, currently accounting for just 3% of the total insurance market, is slowly gaining momentum. Growth catalysts are rapidly emerging, given that as the country transforms itself into a value-added economy, public hospitals are coming under mounting pressure to control costs and improve quality, both areas in which commercial insurers have a strong role to play, experts say.
You may also be interested in...
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
China Biotech Podcast: BIOSECURE Updates, Genmab/ProfoundBio Deal
In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.